MedTrace Logo

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

NCT03173976 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-11-06

No results posted yet for this study

Summary

The purpose of this single arm open label phase 1b clinical study is to see what effect zoledronic acid has on tumors in patients with resectable any grade chondrosarcoma prior to surgery.

Conditions

  • Chondrosarcoma

Interventions

DRUG

Zoledronic Acid

Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.

Sponsors & Collaborators

  • Rising Tide Foundation

    collaborator OTHER

  • Mohammed Milhem

    lead OTHER

Principal Investigators

  • Mohammed Milhem, MBBS · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-18
Primary Completion
2023-04-20
Completion
2028-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03173976 on ClinicalTrials.gov